Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Deep Lens was an artificial intelligence (AI) company dedicated to accelerating cancer clinical trial recruitment by identifying and matching eligible patients more effectively. Their flagship software, VIPER (Virtual Imaging for Patient Evaluation and Recruitment), automated the screening process, helping to bring new cancer therapies to patients faster. Founded in 2017, Deep Lens made significant strides in the oncology space before being acquired by Paradigm in October 2022. Paradigm was subsequently acquired by Exact Sciences in March 2024. Deep Lens's technology and expertise are now integrated into Exact Sciences' precision oncology portfolio.
Historically, the primary center for research and development of its AI platform (VIPER), software engineering, business operations, and strategic partnerships. These functions are now integrated within Exact Sciences.
Located within The Ohio State University's Innovation District, fostering collaboration and access to research talent. The facility likely featured modern office space designed for a technology-focused company.
As a startup, Deep Lens fostered an innovative, agile, and mission-driven work culture focused on solving critical challenges in oncology. There was an emphasis on collaboration, technological excellence, and making a tangible patient impact.
The Columbus headquarters was central to Deep Lens's growth and its role in advancing AI applications in healthcare, particularly for clinical trial optimization within the Midwest tech ecosystem. It represented a key player in Ohio's burgeoning biotech scene.
As an independent entity, Deep Lens primarily served the U.S. market, collaborating with cancer centers, research institutions, and pharmaceutical companies nationwide. Its VIPER platform, designed for clinical trial recruitment, had the inherent potential for global application. Post-acquisition, its technology and capabilities contribute to Exact Sciences' broader global operations and reach in precision oncology.
1275 Kinnear Rd
Columbus
OH
USA
Address: N/A
N/A
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Deep Lens (acquired by Paradigm)' leadership includes:
Deep Lens (acquired by Paradigm) has been backed by several prominent investors over the years, including:
Deep Lens was acquired by Paradigm in October 2022, and Paradigm was subsequently acquired by Exact Sciences in March 2024. Key Deep Lens executives transitioned to roles within the acquiring entities. Therefore, no specific 'Deep Lens' executive hires or exits have occurred in the last 12 months as it no longer operates as a standalone company. The most significant 'change' was the integration of its leadership into Paradigm and then Exact Sciences.
Discover the tools Deep Lens (acquired by Paradigm) uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition and integration, Deep Lens, Inc. likely used common corporate email formats based on its domain deeplens.ai. Typical patterns for technology companies include first initial followed by last name, or first name separated by a dot from the last name.
[first_initial][last]@deeplens.ai (e.g., jdoe@deeplens.ai) or [first].[last]@deeplens.ai (e.g., jane.doe@deeplens.ai)
Format
sarkell@deeplens.ai
Example
70%
Success rate
PR Newswire • October 25, 2022
Paradigm announced its acquisition of Deep Lens, Inc., an AI company focused on clinical trial matching. The acquisition aimed to accelerate patient access to clinical trials by combining Paradigm's clinical research expertise with Deep Lens's VIPER platform....more
Fierce Biotech • March 3, 2021
Deep Lens secured $16 million in a series B funding round led by Northpond Ventures. The funding was aimed at expanding its AI-driven clinical trial recruitment platform, VIPER, and growing its network of cancer centers....more
Exact Sciences Newsroom • March 7, 2024
Exact Sciences announced the completion of its acquisition of Paradigm, the company that had previously acquired Deep Lens. This move integrates Deep Lens's foundational AI technology for trial matching further into Exact Sciences' comprehensive offerings for precision oncology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Deep Lens (acquired by Paradigm), are just a search away.